ALLR
Allarity·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALLR
Allarity Therapeutics, Inc.
A clinical-stage biopharmaceutical company engages in developing oncology therapeutics
123 E Tarpon Ave, Tarpon Springs, FL 34689
--
Allarity Therapeutics, Inc., was incorporated in Delaware on April 6, 2021. The Company is a clinical-stage biopharmaceutical company addressing some of the largest unmet needs in oncology by developing differentiated novel therapeutic candidates with a precision medicine approach and its proprietary DRP companion diagnosis. The company uses its proprietary DRP predictive biomarker platform to select patients they believe are the most responsive to their therapeutic candidates.
Company Financials
EPS
ALLR has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.23, beating expectations. The chart below visualizes how ALLR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
